USANA Q4 net sales $267M (-14% YoY), EPS $1.03; FY22 guidance $5.25-$6.00 EPS

USANA HEALTH SCIENCES INC

2022-FY EPS reported $5.73 revenue$1,186,464,000

Q4 net sales $267.3M (-14% YoY), diluted EPS $1.03 (-45% YoY); active customers 560K (-7% YoY).
FY2021 net sales $1.186B (+5% YoY); diluted EPS $5.73 (-2% YoY); FX benefit $53.6M.
FY2022 guidance: net sales $1.125-$1.225B; diluted EPS $5.25-$6.00; expects net sales acceleration.
Q4 regional: Asia Pacific -15%, Americas/Europe -11%; COVID disruptions hurt key markets; Southeast Asia Pacific -26%.
Ended Q4 with $240M cash, no debt; repurchased 296K shares for $28.9M; $108M buyback remaining.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.